Q3 2022 · 13F-HR
Revelation Capital Management, LLCholdings as filed
Filed 2022-11-07 · accession 0000950123-22-010986
$4,257
Reported value
3
Positions
2022-09-30
Period end
The Brief · Revelation Capital Management, LLC · Q3 2022
AI · grounded in 13F
Revelation Capital Management, LLC closed its position in ACCDUSD with a decrease of $430. The fund trimmed its holding in NPCE by 82.68%. Additionally, it established a new position in AKILI INC valued at $556.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 82933R100 | — | SINGULAR GENOMICS SYSTEMS INC | $3,540 | 83.2% | 1,415,846 | Common | SOLE |
| 00974B107 | — | AKILI INC | $556 | 13.1% | 245,912 | Common | SOLE |
| 641288105 | NPCE | NEUROPACE INC | $161 | 3.78% | 42,972 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.